Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study).

Bulsei J, Leroy S, Perotin JM, Mal H, Marquette CH, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Salaün M, Marceau A, Dukic S, Barbe C, Bonnaire M, Deslee G, Durand-Zaleski I; REVOLENS study group.

Respir Res. 2018 May 9;19(1):84. doi: 10.1186/s12931-018-0796-x.

2.

Two-year follow-up after endobronchial coil treatment in emphysema: results from the REVOLENS study.

Deslée G, Leroy S, Perotin JM, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Salaün M, Marceau A, Dury S, Benzaquen J, Bonnaire M, Dukic S, Barbe C, Marquette CH; , on behalf of the REVOLENS Study Group13; REVOLENS Study Group.

Eur Respir J. 2017 Dec 21;50(6). pii: 1701740. doi: 10.1183/13993003.01740-2017. Print 2017 Dec. No abstract available.

3.

Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial.

Deslée G, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Thiberville L, Leroy S, Marceau A, Laroumagne S, Mallet JP, Dukic S, Barbe C, Bulsei J, Jolly D, Durand-Zaleski I, Marquette CH; REVOLENS Study Group.

JAMA. 2016 Jan 12;315(2):175-84. doi: 10.1001/jama.2015.17821.

PMID:
26757466

Supplemental Content

Loading ...
Support Center